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Abstract
Background: Alport syndrome (AS) is a rare inherited disorder characterized by an inflammation of the kidneys
and damage to the glomerular capillaries, ultimately leading to renal failure at an early age. To date, rare reports of
cardiac involvement in AS have been described, due in the majority of cases to the higher risk of heart conduction
abnormalities in these patients, at times requiring implantation of a transcutaneous pacemaker. An increased risk of
hypertension is likewise commonly featured.
Case presentation: We report the case of a 17-year-old female affected by a very severe early form of AS.
A previously unreported association of the syndrome with congenital heart disease (CHD), (in this case
membranous ventricular septal defect), is also reported. A possible pathophysiological mechanism underlying the
concomitant manifestation of these two disorders is suggested. Complications implicated in surgical treatment of
CHD are described. Clinical and therapeutic management of AS with cardiovascular involvement are discussed, and
a short literature review performed.
Conclusions: This first report of a cardiovascular association highlights the possible involvement of collagen
mutations in the two pathologies. Even when drug-resistance appears to be responsible for the failure to control
secondary hypertension in AS, clonidine may represent a safe, effective option in the normalization of high blood
pressure.
Background
Alport syndrome (AS), first described by Cecil A. Alport
in 1927, is a rare inherited form of progressive kidney
inflammation (0.3 - 2.3% of patients presenting with
end-stage renal disease) affecting predominantly males.
The disorder is caused by defects in the genes encoding
ac o n n e c t i v et i s s u ep r o t e i n ,o n eo ft h es e v e r a ls u b u n i t s
of collagen (particularly type IV), and a major compo-
nent of the renal glomerular basal membrane [1-5].
Various mutations lead to a broad spectrum of signifi-
cantly different disease phenotypes, ranging from benign
mild renal insufficiency to end-stage renal disease. AS is
inherited by the majority of patients (approx 85%) as an
X-linked trait, although some patients display an autoso-
mal recessive (10-15%) or autosomal dominant (rare)
genetic transmission [6]. As a general rule, severity of
the disease is greater in males with X-linked AS, being
equally severe in male and female homozygotes featur-
ing the autosomal recessive form [7,8]. AS should be
differentiated from other types of chronic glomerulopa-
thies [9]. To this regard, microscopic renal changes in
AS are frequently observed in early biopsy specimens of
renal tissue featuring podocyte hypertrophy and stiffness
of the capillary wall, associated or not with the presence
of tubular red blood cell casts. Focal and segmental
thickening of the glomerular basal membrane may also
at times present with progressive enlargement of mesan-
gial stalks. Development of segmental, and subsequently
diffuse, glomerular sclerosis in an increasing number of
glomeruli leads to complete sclerosis. An increase in
size and severity of foci of tubulo-interstitial lesions may
precede marked glomerular changes. Clusters of intersti-
tial foam cells frequently found in proteinuric patients
tend to decrease in end-stage renal disease. No signifi-
cant arterial changes are initially observed [3]. Hema-
turia, the most common and earliest manifestation of
AS, usually occurs in the first years of life, while protei-
nuria is absent and develops throughout childhood into
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generally progresses with age [10]. Hypertension is com-
monly observed in patients affected by AS, with both
incidence and severity increasing with age and degree of
renal failure [11]. Due to collagen involvement in ear
and eye development, hearing and ocular abnormalities
are also present. Deafness is never present at birth, but
may be manifested in late childhood or early adoles-
cence, although some patients affected by AS feature
severe nephropathy but normal hearing. Ocular abnorm-
alities include anterior lenticonus, dot-and-fleck retino-
pathy (85%), and posterior polymorphous corneal
dystrophy. Other systemic manifestations (in particular
leiomyomatosis, and blood disorders) have also been
described [6,12]. No established form of treatment cur-
rently exists for AS. Some patients benefit from angio-
tensin-converting enzyme inhibitors or angiotensin
receptors blockers resulting in the reduction of protei-
nuria and progression of renal disease [13-15]. A strict
control of blood pressure is paramount. Several litera-
ture reports describe the ability of cyclosporine in redu-
cing proteinuria and stabilizing renal functions, although
diverging opinions are reported and further studies
should be undertaken to better define the effect of the
drug in AS patients [16,17]. In patients with severe renal
failure, dialysis treatment is usually recommended.
Moreover, subjects with end-stage renal disease invari-
ably undergo kidney transplant, with 3-5% of patients
developing an autoimmune reaction in the first year
after transplant (anti-glomerular basal membrane
nephritis) with loss of allograft [18]. Here we report the
case of a female adolescent with a previously unde-
scribed association of AS with congenital heart disease
(CHD), i.e. a membranous ventricular septal defect
(VSD). The possible pathophysiological mechanism
underlying these two disorders is hypothesized. Surgical
treatment of VSD and the complications arising is
described, and the clinical and therapeutic management
of AS discussed.
Case presentation
A 17-year-old female was referred to our clinical Centre
due to difficulty in controlling her blood pressure by
means of treatment with angiotensin-converting enzyme
(ramipril 10 mg/day), angiotensin receptor blockade
(losartan 100 mg/day), calcium antagonist (nifedipine
10 mg/day) and alpha lithic (doxazosin 4 mg/day). The
patient was affected by an early onset, extremely aggres-
sive form of AS (X-linked type, due to a nonsense muta-
tion in the COL4A5 gene), with development of severe
renal insufficiency requiring treatment with dialysis
(three sessions/week). Additionally, the patient had a his-
tory of moderate membranous VSD treated by surgery at
the age of one year. Physical examination underlined the
minuteness of the subject (height 151 cm; weight 44 Kg;
BMI 19.3 Kg/m
2). Systemic blood pressure was 157/94.
The patient presented with perimalleolar oedema of the
legs. Heart sounds were rhythmic with no murmur. Basal
lung auscultation revealed crackling wheezes. Electrocar-
diogram revealed sinus rhythm with heart rate 92 beats/
min. Chest X-ray revealed a normal heart size, and a
more marked pulmonary vasculature, particularly at basal
level (Figure 1). Transthoracic echocardiography revealed
complete surgical closure of VSD, with no signs of intra-
cardiac shunt (Figures 2, and 3). The two ventricular
chambers were well balanced and pulmonary arterial
pressure - calculated from tricuspid valve insufficiency -
was normal. Surgery performed to close the VSD with a
bovine pericardial patch had been complicated by devel-
opment of a transient complete atrioventricular block
lasting seven days and promptly treated with a temporary
pace maker. The patient was discharged from hospital
two weeks after surgery in good clinical conditions. A
24-hour ambulatory blood pressure monitoring (ABPM)
was performed to better define daily blood pressure
variability, in particular to avoid a possible white coat
effect, and evaluate drug-resistance. ABPM analysis
(Figure 4) highlighted a persistent elevation in both systo-
lic and diastolic blood pressure. Physiological decline in
nocturnal pressure was also absent (non-dipper pattern).
As treatment prescribed was not capable of adequately
controlling the patient’s blood pressure, add-on therapy
Figure 1 Chest antero-posterior X-ray showing a normal heart
size, and a more marked pulmonary vasculature, particularly at
basal level. A central venous catheter is evident as well.
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patch applied to the skin every 7 days). After two weeks
the patient’s blood pressure had normalized. Following
the development of cutaneous rush at the site of patch
application, after 1 month transdermal clonidine was
replaced with oral clonidine (150 mg × 3/day), achieving
the same satisfactory effect in controlling blood pressure.
Discussion
Cardiac involvement in AS is very rare. Literature
reports refer a higher risk of heart conduction abnorm-
alities in patients with AS. Even patients with a normal
preoperative electrocardiogram or no conduction system
disorders may present some degree of atrioventricular
block, including complete atrioventricular block [19].
Generally speaking, this could reflect [19]:
a. an increase in conduction disorders caused by renal
failure due to abnormalities in calcium metabolism lead-
ing to fibrosis and myocardial calcification;
b. high serum potassium levels. Although sinoatrial and
atrioventricular nodes are apparently less sensitive to
hyperkalemia than other cardiac fibers - owing to their
calcium-dependent electrophysiological properties -
atrioventricular block due to hyperkalemia may occur;
c. an external sympathetic block due to anaesthesia.
Furthermore, surgery for VSD closure is frequently
complicated by the development of atrioventricular
blocks. However, AS patients may have an additional
risk in developing this surgical complication. In such
cases, including the case described here, a transcuta-
neous pacemaker provides rapid and effective treatment
in the operating room, thus facilitating the scheduling of
definitive treatment. In addition, isolated case reports of
arterial disease in males with AS, including dissection
and aneurysm have been published. Immunohistochem-
istry bioptic findings have confirmed the abnormal
absence of several type IV collagen chains from the aor-
tic media of these patients. Accordingly, the routine
screening of males with AS for aortic abnormalities may
be clinically indicated [20]. To date however, and to the
best of our knowledge no association between AS and
any forms of CHD has been described. In our patient,
Figure 2 Transthoracic echocardiogram: parasternal log axis view showing septal paradoxical movement at M-mode modality.
Figure 3 Closure of the ventricular septal defect by a patch
(white arrow).
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duced a left to right shunt, initially treated by diuretic
therapy (furosemide 1 mg/Kg × 2/day). At the age of
one year, surgical treatment was recommended and the
VSD closed by means of a pericardial patch. As stated
above, surgery was complicated by the development of a
transient atrioventricular block, treated with a tempor-
ary pace maker. With regard to the possible pathophy-
siological mechanism underlying the association of AS
and VSD, it should be borne in mind that the membra-
nous portion of the interventricular septum consists of
tough collagenous fibrous connective tissue, thus sug-
gesting the involvement of collagen formation defects in
the pathogenesis of membranous VSD [21,22]. Even if
type IV collagen is mainly involved in glomerulosclerosis
of AS kidneys, it would seem the mutations affecting the
Alport gene also have secondary effects on the distribu-
tion of other types of collagen at the level of glomerular
basal membrane constituents. These other types, which
may also be involved in the development of VSD, might
just be the link between these two so apparently differ-
ent pathologies.
However, the above mechanism is merely putative and
further studies should be undertaken to better clarify the
relationship between the two disorders. This will likely
n o tb ea ne a s yt a s kd u et ot h er a r i t yo fA l p o r td i s e a s e .
With regard to cardiovascular involvement in AS, high
blood pressure is a common feature manifested second-
ary to renal failure [23]. In our patient, blood pressure
was only normalized following the addition of clonidine
to the previously established pharmacological therapy.
Clonidine, which is not a first line drug in most cases of
hypertension, is a direct-acting a2 adrenergic agonist
that controls high blood pressure through stimulation of
a2 receptors in the brain, leading to a decrease in cardiac
output and peripheral vascular resistance, in turn result-
ing in a lowering of blood pressure. The drug may how-
ever produce side effects such as lightheadedness, dry
mouth, dizziness, constipation, and hypotension. Cloni-
dine also features peripheral alpha agonist effects, which
may lead to the onset of hypertension. The latter effects
may be observed following an overdose in children, as
blood pressure increases. As clonidine is eliminated by
the body, its peripheral effects wear off, and central hypo-
tensive effects become visible. Both hypertensive and
hypotensive effects may be harmful. Indeed, sudden dis-
continuation of the drug may elicit rebound hypertension
due to a rebound in sympathetic outflow [24]. To this
regard the utility of ABPM in monitoring daily blood
pressure variability even in patients with end-stage renal
disease undergoing dialysis is evident [25].
Lastly, the present case report is of particular interest
in view of the high degree of severity of AS in such a
young female, as the more severe forms of X-linked AS
are generally manifested in males, with a later onset of
end-stage renal disease.
Conclusions
In conclusion, this previously unreported association of
AS with CHD has contributed towards furthering insight
into this rare disease. A mutation at the level of collagen
synthesis may explain the concomitant presentation of
Figure 4 24-hour ambulatory blood pressure monitoring profile showing a persistent elevation of both systolic and diastolic blood
pressure. The physiological decline in nocturnal pressure was absent (non-dipper pattern).
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to underlie the failure to control secondary hypertension
in AS, clonidine may represent a safe, effective addition
capable of normalizing high blood pressure [26].
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